Trials / Completed
CompletedNCT03025542
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Based on their randomization subjects will receive a combination of several injections of Bimekizumab. |
| OTHER | Placebo | Subjects will receive injections of Placebo. |
Timeline
- Start date
- 2016-12-27
- Primary completion
- 2017-12-11
- Completion
- 2017-12-11
- First posted
- 2017-01-19
- Last updated
- 2026-03-24
- Results posted
- 2021-01-06
Locations
8 sites across 4 countries: United States, Australia, Canada, Moldova
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03025542. Inclusion in this directory is not an endorsement.